These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24289783)

  • 1. Basic research funding by philanthropic organizations: a case in point.
    Chignard M; Ramphal R
    Am J Respir Crit Care Med; 2013 Dec; 188(11):1376-8. PubMed ID: 24289783
    [No Abstract]   [Full Text] [Related]  

  • 2. Straight talk with... Robert Beall. Interviewed by Elie Dolgin.
    Beall R
    Nat Med; 2012 Mar; 18(3):335. PubMed ID: 22395687
    [No Abstract]   [Full Text] [Related]  

  • 3. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 4. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.
    Cohen D; Raftery J
    BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379
    [No Abstract]   [Full Text] [Related]  

  • 5. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 6. Public-private partnerships in health care for developing countries: a new paradigm for change.
    Ahn M; Herman A; Damonti J
    Manag Care Q; 2000; 8(4):65-72. PubMed ID: 11146847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis in an era of genomically guided therapy.
    Barrett PM; Alagely A; Topol EJ
    Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

  • 9. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 10. Transformative mutation specific pharmacotherapy for cystic fibrosis.
    Sanders DB; Farrell PM
    BMJ; 2012 Jan; 344():e79. PubMed ID: 22232540
    [No Abstract]   [Full Text] [Related]  

  • 11. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 12. Philanthropy, medical research, and the role of development.
    Wheeler JL; Rum SA; Wright SM
    Am J Med; 2014 Oct; 127(10):903-4. PubMed ID: 24858063
    [No Abstract]   [Full Text] [Related]  

  • 13. Cystic fibrosis in the era of genomic medicine.
    Milla CE
    Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic ivacaftor treatment: getting F508del-CFTR into more trouble?
    Mall MA; Sheppard DN
    J Cyst Fibros; 2014 Dec; 13(6):605-7. PubMed ID: 25458465
    [No Abstract]   [Full Text] [Related]  

  • 15. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting a cystic fibrosis mutation opens door for personalized treatment.
    Morrow T
    Manag Care; 2012 Apr; 21(4):53-4. PubMed ID: 22590787
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 18. The Role of Philanthropic Funding in Building Research Evidence to Support an Aging Population: A Case Study from Ireland.
    Cochrane A; McGilloway S
    J Aging Soc Policy; 2017; 29(3):262-275. PubMed ID: 28362228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 20. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
    Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.